<DOC>
	<DOCNO>NCT00917150</DOCNO>
	<brief_summary>To investigate efficacy safety OPC-6535 COPD patient , use measurement trough FEV1 time primary endpoint .</brief_summary>
	<brief_title>To Investigate Efficacy Safety OPC-6535 Chronic Obstructive Pulmonary Disease ( COPD ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>Age 40 75 year , inclusive , time informed consent obtain Ability provide write informed consent Agree use appropriate method contraception 3 month last dose investigational medicinal product ( IMP ) A rating 1 high Goddard scale assessment emphysema severity chest CT scan screening Ratio force expiratory volume 1 second force vital capacity ( FEV1/FVC ) less 70 % screen Cigarette smoke history least 20 pack year screen Subjects obstructive disorder due bronchial asthma Subjects receive longterm oxygen therapy Subjects active tuberculosis obvious bronchiectasis Complication malignant tumor Uncontrolled cardiovascular , endocrine , blood , nervous system disorder Uncontrolled condition COPD exacerbation level 2 3 within 8 week prior start washout period ( within 12 week prior start treatment period )</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>chronic obstructive pulmonary disease</keyword>
	<keyword>COPD</keyword>
	<keyword>emphysema</keyword>
</DOC>